ADM WILD Valencia S.A.U. – Trademark Portfolio

Entity Type: 99

ADM WILD Valencia S.A.U. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include CAROUP.

Partida La Coma s/n

E-46740 Carcaixent (Valencia)

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CAROUP
CAROUP
Registered 2021
CAROUP
CAROUP
Registered 2021

Trademark Classifications

ADM WILD Valencia S.A.U.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does ADM WILD Valencia S.A.U. have?

ADM WILD Valencia S.A.U. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does ADM WILD Valencia S.A.U. file in?

ADM WILD Valencia S.A.U. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are ADM WILD Valencia S.A.U.'s most well-known trademarks?

ADM WILD Valencia S.A.U.'s registered trademark portfolio includes well-known marks such as CAROUP. These are among 2 currently registered trademarks in the portfolio.

What is ADM WILD Valencia S.A.U.'s trademark registration success rate?

ADM WILD Valencia S.A.U. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.